125
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Gentiopicroside Inhibits Cell Growth and Migration on Cervical Cancer via the Reciprocal MAPK/Akt Signaling Pathways

, , , , &
Pages 1459-1470 | Received 30 Sep 2019, Accepted 03 Jul 2020, Published online: 07 Aug 2020
 

Abstract

Cervical cancer (CC) is a common gynecological malignancy and represents a major global health challenge. Chemotherapeutic agents are commonly applied in treatment of CC, while along various adverse effects and chemotherapy resistance. As an iridoid glycoside compound, gentiopicroside (GPS) possesses the characteristic of the better availability and lower toxicity effect on cancer treatment. In the present study, we investigated that GPS exhibited the anticancer effect on HeLa cells through the inhibition of cell growth, induced apoptosis, cycle arrest, and suppressed migration. Furthermore, the possible mechanism or the targets of GPS was also clarified. The results revealed that GPS exerted an anti-proliferation effect in a dose- and time-dependent manner in HeLa cells, in contrast, with the less inhibiting proliferation effects on normal cell line (HUVEC). Moreover, GPS arrested cells at G2/M phase and induced apoptosis through mitochondrial apoptotic pathway. More significantly, GPS dramatically inhibited the migration of HeLa cells and regulated the matrix metalloproteinase expression through the MAPK and Akt signaling pathways, of which MAPK1 was an underlying target in GPS against HeLa cells.

Disclosure Statement

The authors have declared no conflict of interest.

Additional information

Funding

This work was supported by the Key Research and Development Project of Ningxia (Grant No. 2019BEG03040) and the Scientific Research Project of Ningxia Medical University (Grant No. XY201820).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.